1. Introduction {#sec1}
===============

Sepsis is a deregulated body response to infection, triggering inflammatory reactions that can cause systemic symptoms and damage multiple organs. Release of cytokines mediates uncontrolled inflammatory cascades that result in dysfunction and failure of multiple major organs and septic shock \[[@B1], [@B2]\]. Managing infection is the most critical strategy for sepsis therapy. However, these treatments could cause various side effects \[[@B3]\]. Clinically, sepsis is managed with early use of antibiotics and glucocorticoids. Traditional Chinese medicine, including Xuebijing injection \[[@B2], [@B4]\], Shenfu injection \[[@B5]\], and SMI \[[@B6]\], provides supportive effects in sepsis treatment.

Shengmai injection (SMI) origins from the ancient prescription of Chinese medicine Shengmaiyin; it contains Ginsen Radix et Rhizoma Rubra, *Ophiopogon japonicus*, and Schisandrae Chinensis Fructus. It invigorates Qi, nourishes Yin, and promotes blood circulation. SMI is used as add-on for supportive treatment in managing patients with sepsis, systemic inflammatory syndrome, and septic or hemorrhagic shock \[[@B7]--[@B9]\]. The frequency of adverse events associated with SMI is low \[[@B10], [@B11]\]. There have been few reports on the evaluation of SMI effective components and their underlying mechanisms despite they are used as supportive interventions for sepsis treatment. It is a compound with multiple components targeting multiple molecular networks; exploring its complex antisepsis mechanism in a suitable model is of great importance for sepsis treatment \[[@B12]\]. Network pharmacology is a useful tool for systemic investigation of the mechanisms of multiple component drugs \[[@B13], [@B14]\]. Its approach has been used to study "compound-protein/gene-disease" pathways which reveal complexities among drugs, biological systems, and diseases from a network perspective. Network pharmacology provides insights into the complex interrelationships between the active ingredients of traditional Chinese compounds and molecular mechanisms \[[@B15]\].

We established a fingerprint method to detect and represent chemical information of SMI. We mapped potential targets of SMI bioactive ingredients that may regulate the progress of sepsis using a network pharmacology approach. Our findings shed light on further understanding of the mechanisms of SMI in treating complex diseases such as sepsis.

2. Materials and Methods {#sec2}
========================

2.1. Equipment and Reagents {#sec2.1}
---------------------------

Water Acquity H-class UPLC, equipped with quaternion high-pressure pump, automatic sampler, and PDA detector (Milford, USA); METTLER AB265-S electronic analytical balance (Zurich, Switzerland); and SB25-12DT ultrasonic cleaner (Ningbo, China) were used. Standard ginsenoside Rb1 (no. 171018), ginsenoside Rb2 (no. 171009), ginsenoside Rd (no. 170530), ginsenoside Re (no. 170924), ginsenoside RF (no. 171126), ginsenoside Rg1 (no. 180105), Ophiopogon D (no. 171126), schisandrol A (no. 180109), and schisandrin A (no. 171231) were all purchased from Shanghai Ronghe Medical Pharmaceutical Technology Co., Ltd (Shanghai, China). Ginsenoside Rb3 (no. 111686-201504) and ginsenoside Rg2 (no. 111779-200801) were purchased from the National Institutes for Food and Drug Control (Beijing, China). The purity of all of the above standards was above 98.0%. Acetonitrile and methanol were purchased from Merck (chromatographically pure, Darmstadt, Germany). Distilled water was purchased from Watson (Hong Kong, China). There were 9 batches of SMI: S1, 16120401005; S2, 160502; S3, 17071014; S4, 17040423; S5, 1704252; S6, 17091302; S7, 17092903; S8, 17061103; and S9, 17053005.

2.2. Standards and Sample Solution Preparation {#sec2.2}
----------------------------------------------

Standard stock solutions of ginsenoside Rb1 (9.49 mg), ginsenoside Rb2 (10.22 mg), ginsenoside Rb3 (6.69 mg), ginsenoside Rd (6.24 mg), ginsenoside Re (6.24 mg), ginsenoside Rf (7.35 mg), ginsenoside Rg1 (13.24 mg), ginsenoside Rg2 (6.58 mg), Ophiopogon D (5.12 mg), schisandrol A (5.60 mg), and schisantherin A (3.27 mg) were dissolved in 5 ml methanol followed by sonication, respectively. Mixture of standard solution was filtered through the 0.22 *μ*m membrane in a 5 mL volumetric flask. Final concentration of each standard in the mixture was 37.96, 40.88, 26.76, 24.96, 24.96, 29.40, 52.96, 26.32, 20.48, 17.92, and 10.46 *μ*g·mL^−1^, respectively. SMI solution of each batch was filtered through the 0.22 *μ*m membrane before analysis.

2.3. UPLC Conditions {#sec2.3}
--------------------

The analyte was separated by a Waters Acquity UPLC BEH C18 (2.1 mm × 50 mm, 1.7 *μ*m) column. The mobile phases used were solvent *A* (acetonitrile) and solvent *B* (water) with gradient elution ([Table 1](#tab1){ref-type="table"}). The analysis was carried out at a flow rate of 0.3 mL/min. The column temperature was set to 40°C. UV detection wavelength was over the range of 190 to 400 nm. 5 *μ*L of the sample was injected. 210 nm was selected as the extraction wavelength of the fingerprints.

2.4. Precision of the Method {#sec2.4}
----------------------------

Method precision was determined by analyzing the same sample SMI (S1, 16120101005) five consecutive times in a day. The peak of schisantherin A was used as the reference peak. Relative standard deviation (RSD) was calculated from the relative peak area (RPA) or relative retention time (RRT) of each characteristic peak.

2.5. Sample Stability {#sec2.5}
---------------------

Sample stability was evaluated using the same SMI (S1, 16120401005) after 0, 2, 4, 6, 8, 12, and 24 hours. The peak of schisantherin A was used as the reference peak. RSD was calculated from RPA or RRT of each peak to the reference peak from the chromatographic profiles of samples.

2.6. Repeatability {#sec2.6}
------------------

Repeatability was evaluated by analyzing six independently prepared SMI samples. The peak of schisantherin A was used as the reference peak. RSD was calculated from RPA or RRT of each peak to the reference peak from the chromatographic profiles of samples.

2.7. Information about Databases and Software of Network Pharmacology {#sec2.7}
---------------------------------------------------------------------

TCMSP database (<https://tcmspw.com/tcmsp.php>), PubChem CID (<https://pubchem.ncbi.nlm.nih.gov/search/>), STITCH (<http://stitch.embl.de/>), Human Phenotype Ontology (HPO, <https://hpo.jax.org/app/),> STRING database (<https://string-db.org>), OMIM database (<https://omim.org/>), and DAVID database (<https://david.ncifcrf.gov/summary.jsp>) were used. Cytoscape software v3.5.1 was used.

2.8. Network Construction {#sec2.8}
-------------------------

Data acquisition and processing were done in databases which include SciFinder and TCMSP. Additionally, PubChem CID for each active ingredient of SMI was obtained from PubChem. We used SMILES format in STITCH chemical association networks and obtained the interaction complex between SMI bioactive components and the potential target protein in humans. Using HPO as a tool, we annotated and analyzed the core protein targets that participate in sepsis. The primary as well as predicted interactions between SMI target proteins and proteins involved in sepsis were analyzed in the STRING database. We collected core proteins that are highly associated with sepsis, while proteins with low correlation were filtered out \[[@B16]\]. The molecular interplays between SMI key targets and sepsis proteins were visualized in the Cytoscape platform. We calculated the degree, betweenness, and closeness of the targets; proteins with topological parameters greater than the corresponding median values were considered as major hits. The selected proteins were validated in the OMIM database to establish protein-disease association and construct "SMI Targets-Sepsis Targets" network.

2.9. Prediction of the SMI-Antisepsis Mechanism {#sec2.9}
-----------------------------------------------

A list of the selected top 20 key proteins was uploaded to the DAVID database for functional annotation and enrichment analysis to obtain the main pathways and network distribution that confer potential mechanisms for SMI treatment. Only pathways with *p* \< 0.05 were considered for mechanism prediction.

3. Results and Discussion {#sec3}
=========================

3.1. Establishment of SMI Fingerprints and the Results of Methodological Evaluation {#sec3.1}
-----------------------------------------------------------------------------------

The RSDs of RPA and RRT for precision, repeatability, and sample stability were lower than 3%, respectively. The results showed that the fingerprint method developed for analysis of SMI is reliable and applicable. Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} show the UPLC chromatogram fingerprints of 9 batches of SMI.

3.2. Reference Peak and Common Peak {#sec3.2}
-----------------------------------

The peak of schisantherin A was used as the reference peak; it showed as an intense peak with preferable chromatographic peak resolution and RRT. Peaks that existed in all SMI samples were appointed as "common peaks." 44 common peaks were detected in SMI samples, in which 11 peaks were identified ([Figure 3](#fig3){ref-type="fig"}): ginsenoside Rg1 (peak \#10), ginsenoside Re (peak \#11), ginsenoside Rf (peak \#15), ginsenoside Rb1(peak \#19), ginsenoside Rb2 (peak \#20), ginsenoside Rb2 (peak \#22), ginsenoside Rb3 (peak \#23), schisandrol A (peak \#24), ginsenoside Rd (peak \#25), Ophiopogonin D (peak \#37), and schisantherin A (peak \#39).

3.3. Similarity of Fingerprints of 9 Batches of SMI {#sec3.3}
---------------------------------------------------

The similarities of all chromatographic patterns among the samples ([Table 2](#tab2){ref-type="table"}) were calculated using software "Chromatographic Fingerprints of Traditional Chinese Medicine, version: 2004A." The similarities of 9 SMI batches were greater than 0.91. Therefore, our method was precise, stable, reproducible, and reliable.

3.4. Putative Targets of SMI Ingredients {#sec3.4}
----------------------------------------

The SMI components were screened by TCMSP, and the criteria are OB (oral bioavailability) ≥ 30% and, meanwhile, DL (drug-like) ≥ 0.18 \[[@B17]--[@B19]\]. All the components were confirmed in the PubChem database \[[@B19]\] (total 9 bioactive SMI components: ginsenoside Rb1, ginsenoside Rb2, ginsenoside Re, ginsenoside Rf, ginsenoside Rg1, ginsenoside Rg2, schisandrol A, schisantherin A, and Ophiopogon D. Their chemical structures and molecular properties were analyzed and uploaded to the STITCH database for predicting targets that interact with SMI ingredients \[[@B20]\]. A total of 62 targets ([Figure 4](#fig4){ref-type="fig"} and [Table 3](#tab3){ref-type="table"}) showed potential interaction with 9 SMI ingredients.

3.5. Acquisition of Known Therapeutic Sepsis Targets {#sec3.5}
----------------------------------------------------

Sepsis targets were collected from the HPO database. The keyword "sepsis" was used to search known therapeutic targets for sepsis in humans \[[@B21]\]. A total of 58 sepsis targets ([Table 4](#tab4){ref-type="table"}) were acquired from the HPO database, and targets were further verified in the NCBI database.

3.6. Results of Network Construction {#sec3.6}
------------------------------------

The putative targets of SMI active ingredients and sepsis disease targets were determined based on the protein-protein interactions \[[@B22]\]. The interplays amongst SMI targets, known therapeutic targets for sepsis, and interactional human targets were combined to construct the network. The network illustrates the relationship between SMI targets and sepsis targets. The overall interaction network ([Figure 5](#fig5){ref-type="fig"}) was visualized using Cytoscape (sepsis targets in red circles and SMI targets in blue squares); the larger a node, the more targets it contains and more important in sepsis management. Targets with higher values of "degree," "betweenness," "closeness," and "coreness" (above the median value of all the network nodes) were identified \[[@B23], [@B24]\]. Targets which might play unimportant roles in the network according to the topological features were discarded \[[@B25]\]. Median value of "degree," "betweenness," and "closeness" was 19, 0.014, and 0.449, respectively. Top twenty proteins were selected as key sepsis therapeutic targets ([Figure 6](#fig6){ref-type="fig"} and [Table 5](#tab5){ref-type="table"}), including ABL1, CCND1, CDK family (CDK1, CDK2, CDK6, and CDKN1B), RB1, HSP90AA1, SMARCA4, RBL2, CTNNB1, MDM2, SP1, LRRK1, BTK, PIK3R1, TMPRSS11D, ACTG2, CD79A, and RET.

Sepsis causes life-threatening organ dysfunction due to a host\'s complex systemic inflammatory response to infection \[[@B26]\]. In the present study, we identified core proteins that may play important roles in SMI-supportive treatment in sepsis. ABL1 is a tyrosine-protein kinase which is important for cell growth and survival, cytoskeleton remodeling in response to extracellular stimuli, autophagy, and apoptosis \[[@B27]--[@B29]\]. It also regulates multiple pathological signaling cascades during infection that alter vascular permeability and the endothelium barrier in inflammation \[[@B30]\].

Cyclin-dependent kinase 1 (CDK1) is a member of the Ser/Thr protein kinase family. Its kinase activity is controlled by cyclin \[[@B31], [@B32]\]. CCND1/CDK4 and CDK2 are critical for G1/S phase transition. It has been shown rat kidney injury is associated with G1 phase arrest in cecal ligation and puncture- (CLP-) induced sepsis, while upregulation of CCND1/CDK4 and CCNE/CDK2 activates Rb leading to revival of cell cycle progress and recovery of kidney function 48 hours after CLP \[[@B33], [@B34]\]. The findings demonstrate that cell cycle arrest occurs in sepsis, and drugs that regulate cell cycle proteins may be a means to rescue organ injury \[[@B35]\]. In addition, the targets of SMI are more involved in DNA replication and transcription; for example, MDM2, E3 ubiquitin ligase, mediates ubiquitination and degradation of p53. It mediates apoptosis in organ injury and malignant transformation \[[@B36]\]. SMI may inhibit MDM2 and keep p53 active; therefore, it promotes cells staying in the G1/G2 phase and alleviates cell injury in sepsis.

Molecular chaperone heat-shock protein (HSP 90) is extensively expressed by cells, and its expression increases upon stimulation \[[@B37]\]. HSPs are associated with multiple organ failure in sepsis \[[@B38]\]. In the vast immune response in sepsis, stressed cells release HSPs that are regarded as "danger signal" to neighboring and immune cells \[[@B39]\]. HSP90-*α* has been shown to interact with about 200 client proteins, including signal proteins in the inflammatory pathway such as NF-*κ*B, Akt, and IKK, to interfere inflammation \[[@B40]--[@B42]\]. Moreover, HSP90-*α*, as abundant "chaperone," is one of the main mediators that activates bacteria lipopolysaccharide. It interacts with proteins in the PI3K/Akt pathway and is essential in promoting the immune response and improving host defense to pathogens. Inhibition of HSP90-*α* prevents severe sepsis-associated acute lung injury; therefore, block HSP90-*α* offers a novel treatment for lung injury in sepsis \[[@B43]--[@B45]\].

BTK (tyrosine-protein kinase) is a component of the toll-like receptor (TLR) pathway and plays important roles in innate and adaptive immunity. Key target CD79A is required for efficient differentiation of pro- and pre-B-cells. It cooperates with CD79B and bounds to the B-cell antigen receptor complex (BCR) for initiation of the signal transduction cascade. It is pivotal in regulating immunity and inflammation \[[@B46]\]. Network pharmacology revealed SMI represses BTK expression/activation, blocks signals through multiple pathways (TLR, B-cell antigen receptor signal, and apoptosis), and consequently ameliorates cell apoptosis and organ injury. SMI acts as a whole, and each formula has its corresponding targets/syndromes; thus, SMI prescription acts on multiple key targets, and the network pharmacology study of SMI provides insights into understanding its fundamental mechanisms.

3.7. KEGG and GO Analysis {#sec3.7}
-------------------------

To cluster the biological functions of SMI and its targets, data were uploaded to KEGG, and results revealed SMI active formulae target pathways including cancer, cell cycle, p53, B-cell receptor, and ErbB pathways ([Table 6](#tab6){ref-type="table"}). SMI regulates the interplay and synergy among the pathways of immunity, inflammation, and apoptosis to protect cellular and organ injury in sepsis. p53 pathway regulates mitochondrial fission and mitochondrial biogenesis via AMPK, and it alters PKM2-dependent glycolysis. Global deletion of PKM2 results in systemic inflammation in mice \[[@B47]\]. Our GO analysis ([Table 7](#tab7){ref-type="table"}) showed that SMI ingredients regulate multiple biological processes including cell cycle, energy metabolism, cellular signal transduction, transcription regulation, and immunity development. Our data indicate the putative role of SMI in alleviating systemic inflammation and deregulating immunity in the host; moreover, it regulates energy utilization and promotes energy homeostasis and therefore ameliorates multiple organ failure associated with sepsis. It is also in agreement with the idea of SMI used in the early phase of sepsis.

4. Conclusion {#sec4}
=============

An UPLC method was developed for analysis of SMI fingerprints. Forty-four peaks were selected as common peaks, of which 11 peaks were identified. The consistency in the chromatograms of 9-batch samples reflects the presence of similar chemical constituents (similarities greater than 0.91). The technique was proven to be useful in SMI quality control. A total of 9 active components of SMI target 20 key proteins including ABL1, CDK, HSP90, BTK, PIK3R1, and CD79A. These proteins are enriched in cell cycle, p53 signaling pathway, B-cell receptor signaling pathway, and ErbB pathway. It is likely that the pharmacological mechanisms of SMI in sepsis treatment are of multiple dimensions that are associated with regulation of cell cycle, energy metabolism, cellular signal transduction, transcription regulation, and immunity development. Further experiments are needed to validate our prediction.

This research was funded by the National Natural Science Foundation of China (no. 81673667), the CAMS Innovation Fund for Medical Science (CIFMS) (nos. 2016-I2M-3-015 and 2017-I2M-B&R-09), Beijing Natural Science Committee-Beijing Education Committee Joint Foundation (no. KZ201910011012), and Science and Technology Projects in Liaoning Province (no. 20170540263).

Data Availability
=================

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
=====================

The authors declare no conflicts of interest.

Authors\' Contributions
=======================

Juan Lu and Xinkai Lyu contributed equally to this work. XC, ZD, and JL conceived, designed, and supervised the project. RC, YY, XL, MD, and XZ performed the experiments. JL and XL integrated all the data and wrote the paper.

![UPLC fingerprints of 9 batches of SMI.](ECAM2020-4956329.001){#fig1}

![Contrast fingerprint of SMI.](ECAM2020-4956329.002){#fig2}

![UPLC chromatogram of SMI and mixed reference at 210 nm: (a) samples of SMI (S1); (b) mixed reference (10, ginsenoside Rg1; 11, ginsenoside Re; 15, ginsenoside Rf; 19, ginsenoside Rb1; 20, ginsenoside Rg2; 22, ginsenoside Rb2; 23, ginsenoside Rb3; 24, schisandrol A; 25, ginsenoside Rd; 37, Ophiopogon D; and 39, schisandrin A).](ECAM2020-4956329.003){#fig3}

![Prediction of component-target of Shengmai injection by STITCH.](ECAM2020-4956329.004){#fig4}

![Prediction of protein interaction between SMI and sepsis by STRING (blue-square nodes are targets of SMI; red circular nodes are targets of sepsis).](ECAM2020-4956329.005){#fig5}

![Key targets of the SMI-sepsis protein interaction network (yellow is the key target; blue-square nodes are SMI targets; and red circular nodes are sepsis targets).](ECAM2020-4956329.006){#fig6}

###### 

Mobile phase and proportion of qualitative and quantitative chromatographic conditions.

  Time (min)   *A* (%)   *B* (%)
  ------------ --------- ---------
  0            19        81
  3            19        81
  12           26.8      73.2
  15           32        68
  23           32        68
  23.1         44        56
  35           66.8      33.2

###### 

Comparison of similarity of Shengmai injection in different batches.

                         S1      S2      S3      S4      S5      S6      S7      S8      S9      Control fingerprints
  ---------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ----------------------
  S1                     1       0.954   0.983   0.976   0.916   0.938   0.944   0.942   0.953   0.968
  S2                     0.954   1       0.943   0.945   0.821   0.869   0.89    0.885   0.922   0.914
  S3                     0.983   0.943   1       0.992   0.931   0.962   0.967   0.965   0.973   0.986
  S4                     0.976   0.945   0.992   1       0.927   0.945   0.952   0.95    0.967   0.978
  S5                     0.916   0.821   0.931   0.927   1       0.944   0.944   0.939   0.931   0.963
  S6                     0.938   0.869   0.962   0.945   0.944   1       0.996   0.996   0.983   0.98
  S7                     0.944   0.89    0.967   0.952   0.944   0.996   1       0.998   0.989   0.984
  S8                     0.942   0.885   0.965   0.95    0.939   0.996   0.998   1       0.989   0.98
  S9                     0.953   0.922   0.973   0.967   0.931   0.983   0.989   0.989   1       0.98
  Control fingerprints   0.968   0.914   0.986   0.978   0.963   0.98    0.984   0.98    0.98    1

###### 

Prediction of pharmacodynamic targets of Shengmai injection.

  No.   Targets
  ----- -----------
  1     E2F5
  2     HDAC2
  3     VPS33A
  4     TFDP2
  5     MSN
  6     KCNE1
  7     RB1
  8     CDK1
  9     TFDP1
  10    MDM2
  11    VPS16
  12    VPS39
  13    E2F4
  14    E2F2
  15    CDK2
  16    VPS41
  17    KCNA4
  18    HSP90AA1
  19    CDK4
  20    CDK6
  21    HDAC1
  22    CCNA2
  23    E2F1
  24    RBBP4
  25    ABL1
  26    SP1
  27    CCND2
  28    E2F3
  29    RBL2
  30    CCNE1
  31    KCNA3
  32    KCNA1
  33    RAF1
  34    GNAS
  35    LRRK1
  36    STMN4
  37    HMOX1
  38    PPP1R3A
  39    RHAG
  40    PTGES3
  41    GNAL
  42    CCND1
  43    CYP3A4
  44    PPIB
  45    LRRK2
  46    GALE
  47    PPIC
  48    RHCE
  49    VPS18
  50    ANGPTL4
  51    ICT1
  52    DLG4
  53    CKS2
  54    TMPRSS11D
  55    KCNQ1
  56    CCNB1
  57    CCNB2
  58    CCND3
  59    CDC20
  60    CDC37
  61    CDC6
  62    CDKN1B

###### 

Prediction of sepsis closely related proteins in the human body.

  No.   Targets
  ----- ---------
  1     CYBB
  2     RMRP
  3     RAG1
  4     RAG2
  5     TGM1
  6     LIG4
  7     SEMA3D
  8     NIPAL4
  9     SEMA3C
  10    TCF3
  11    MYH11
  12    ATP7A
  13    WAS
  14    WIPF1
  15    GALT
  16    HLA-B
  17    G6PC3
  18    DCLRE1C
  19    NRTN
  20    ABCA12
  21    PIK3R1
  22    IGHM
  23    NFKB2
  24    BTK
  25    NCF1
  26    BLNK
  27    APC
  28    LRRC8A
  29    ELANE
  30    ACTG2
  31    CYP4F22
  32    AK2
  33    CD79A
  34    CD79B
  35    NCF2
  36    IKZF1
  37    ALOXE3
  38    NCF4
  39    SERAC1
  40    LIPN
  41    CHD7
  42    IGLL1
  43    RET
  44    PLEC
  45    CTNNB1
  46    ECE1
  47    ADA
  48    IL2RG
  49    ITGB4
  50    GDNF
  51    MUT
  52    ALOX12B
  53    EDN3
  54    EDNRB
  55    IL7R
  56    FERMT3
  57    TFRC
  58    CYBA

###### 

Key targets and topological parameters of the network on SMI in the treatment of sepsis.

  No.   Gene name   Protein name                                                     Degree   Closeness centrality   Betweenness centrality
  ----- ----------- ---------------------------------------------------------------- -------- ---------------------- ------------------------
  1     ABL1        Tyrosine-protein kinase ABL1                                     43       0.548                  0.101
  2     CCND1       G1/S-specific cyclin-D1                                          42       0.522                  0.046
  3     RB1         Retinoblastoma-associated protein                                41       0.509                  0.037
  4     CDK2        Cyclin-dependent kinase 2                                        41       0.52                   0.026
  5     HSP90AA1    Heat-shock protein HSP 90-alpha                                  40       0.531                  0.077
  6     CDK1        Cyclin-dependent kinase 1                                        39       0.509                  0.023
  7     CDK6        Cyclin-dependent kinase 6                                        39       0.502                  0.015
  8     SMARCA4     Transcription activator BRG1                                     37       0.511                  0.037
  9     CDKN1B      Cyclin-dependent kinase inhibitor 1B                             37       0.506                  0.031
  10    RBL2        Retinoblastoma-like protein 2                                    36       0.482                  0.04
  11    CTNNB1      Catenin beta-1                                                   36       0.509                  0.036
  12    MDM2        E3 ubiquitin-protein ligase Mdm2                                 35       0.488                  0.025
  13    SP1         Transcription factor Sp1                                         34       0.504                  0.027
  14    LRRK1       Leucine-rich repeat serine/threonine-protein kinase 1            31       0.515                  0.115
  15    BTK         Tyrosine-protein kinase BTK                                      23       0.486                  0.038
  16    PIK3R1      Phosphatidylinositol 3-kinase regulatory subunit alpha           21       0.47                   0.054
  17    TMPRSS11D   Transmembrane protease serine 11D                                20       0.463                  0.041
  18    ACTG2       Actin, gamma-enteric smooth muscle                               20       0.454                  0.025
  19    CD79A       B-cell antigen receptor complex-associated protein alpha chain   19       0.458                  0.058
  20    RET         Proto-oncogene tyrosine-protein kinase receptor Ret              19       0.463                  0.032

###### 

Analysis of major metabolic pathways related to sepsis in KEGG.

  No.   Name                                Count   *p* value
  ----- ----------------------------------- ------- --------------
  1     Pathways in cancer                  11      6.2 × 10^−9^
  2     Cell cycle                          9       1.2 × 10^−9^
  3     p53 signaling pathway               5       4.7 × 10^−5^
  4     Melanoma                            5       5.6 × 10^−5^
  5     Non-small cell lung cancer          4       5.8 × 10^−4^
  6     B-cell receptor signaling pathway   3       2.3 × 10^−2^
  7     Colorectal cancer                   3       2.8 × 10^−2^
  8     ErbB signaling pathway              3       3 × 10^−2^

###### 

GO biological analysis.

  No.   Name                                                          Count   *p* value
  ----- ------------------------------------------------------------- ------- ---------------
  1     Cell cycle                                                    10      3.5 × 10^−7^
  2     Phosphorylation                                               9       6.1 × 10^−6^
  3     Phosphorus metabolic process                                  9       2.6 × 10^−5^
  4     Intracellular signaling cascade                               9       1.6 × 10^−4^
  5     Regulation of transcription                                   9       1.8 × 10^−2^
  6     Mitotic cell cycle                                            8       4.1 × 10^−7^
  7     Protein amino acid phosphorylation                            8       2.1 × 10^−5^
  8     Positive regluation of macromolecule metabolic process        8       1.0 × 10^−4^
  9     Interphase                                                    7       5.0 × 10^−9^
  10    Regulation of cell proliferation                              7       5.4 × 10^−4^
  11    Regulation of transcription, DNA-dependent                    7       3.0 × 10^−2^
  12    Regulation of RNA metabolic process                           7       3.3 × 10^−2^
  13    Regulation of mitotic cell cycle                              6       2.6 × 10^−15^
  14    Hemopoiesis                                                   6       1.5 × 10^−5^
  15    Hemopoietic or lyphoid organ development                      6       2.4 × 10^−5^
  16    Immune system development                                     6       3.1 × 10^−5^
  17    Positive regluation of nitrogen compound metabolic process    6       1.6 × 10^−3^
  18    Positive regluation of celluar biosynthetic process           6       2.1 × 10^−3^
  19    Positive regluation of biosynthetic process                   6       2.2 × 10^−3^
  20    Regulation of transcription from RNA polymerase II promoter   6       2.7 × 10^−3^

[^1]: Academic Editor: Jeng-Ren Duann
